Log in

NASDAQ:GBTGlobal Blood Therapeutics Stock Price, Forecast & News

$68.76
-1.72 (-2.44 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$67.92
Now: $68.76
$69.78
50-Day Range
$62.66
MA: $69.03
$74.49
52-Week Range
$39.95
Now: $68.76
$87.54
Volume553,590 shs
Average Volume910,431 shs
Market Capitalization$4.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Read More
Global Blood Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.11 million
Book Value$9.61 per share

Profitability

Net Income$-266,770,000.00

Miscellaneous

Employees171
Market Cap$4.19 billion
Next Earnings Date8/5/2020 (Confirmed)
OptionableOptionable
$68.76
-1.72 (-2.44 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

How has Global Blood Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GBT stock has increased by 25.4% and is now trading at $68.76.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Global Blood Therapeutics?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Global Blood Therapeutics
.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Global Blood Therapeutics
.

How can I listen to Global Blood Therapeutics' earnings call?

Global Blood Therapeutics will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($1.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.47) by $0.27. The business earned $14.12 million during the quarter, compared to analyst estimates of $3.65 million. During the same quarter in the prior year, the business earned ($0.87) EPS.
View Global Blood Therapeutics' earnings history
.

What price target have analysts set for GBT?

21 brokers have issued twelve-month price objectives for Global Blood Therapeutics' shares. Their forecasts range from $60.00 to $150.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $105.65 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics
.

Has Global Blood Therapeutics been receiving favorable news coverage?

Media coverage about GBT stock has been trending somewhat positive on Tuesday, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Global Blood Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Global Blood Therapeutics
.

Are investors shorting Global Blood Therapeutics?

Global Blood Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 10,160,000 shares, an increase of 6.3% from the June 15th total of 9,560,000 shares. Based on an average daily trading volume, of 873,900 shares, the short-interest ratio is currently 11.6 days. Approximately 17.1% of the shares of the company are sold short.
View Global Blood Therapeutics' Current Options Chain
.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), TherapeuticsMD (TXMD), Exelixis (EXEL), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ) and Vertex Pharmaceuticals (VRTX).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 60)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
  • Mr. Peter Radovich, Sr. VP of Operations (Age 41)
  • Dr. Hing Sham, Sr. VP of Research (Age 67)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.34%), Botty Investors LLC (0.31%), Frontier Capital Management Co. LLC (0.15%), CWM LLC (0.13%), Candriam Luxembourg S.C.A. (0.11%) and Taylor Wealth Management Partners (0.07%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics
.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, SG Americas Securities LLC, Profit Investment Management LLC, UBS Group AG, Nisa Investment Advisors LLC, Taylor Wealth Management Partners, Janney Montgomery Scott LLC, and ProShare Advisors LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Dawn Svoronos, Deval L Patrick, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, and Tricia Borga Suvari.
View insider buying and selling activity for Global Blood Therapeutics
.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was acquired by a variety of institutional investors in the last quarter, including CWM LLC, Frontier Capital Management Co. LLC, Candriam Luxembourg S.C.A., Peregrine Capital Management LLC, Bfsg LLC, Dupont Capital Management Corp, Brinker Capital Inc., and Fox Run Management L.L.C..
View insider buying and selling activity for Global Blood Therapeutics
.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $68.76.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $4.19 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 181 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.